


**WHAT IS CLAIMED IS:**

## 1. Compounds of Formula I:




5 wherein:

R<sub>1</sub> is hydroxyl, alkoxy of 1-4 carbons, or -O(CH<sub>2</sub>)<sub>n</sub>X;

n is an integer of 1-3;

X is CONHR<sub>6</sub> or CO<sub>2</sub>R<sub>6</sub>;10 R<sub>2</sub> is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF<sub>3</sub>, OCF<sub>3</sub>, SO<sub>2</sub>NHR<sub>6</sub>, NR<sub>6</sub>R<sub>7</sub> or CO<sub>2</sub>R<sub>6</sub>;R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl15 where the aryl group is substituted with R<sub>2</sub>;  
or a pharmaceutically acceptable salt thereof.

## 2. Compounds of Formula II:



20

wherein:

R<sub>1</sub> is hydroxyl, alkoxy of 1-4 carbons, or -O(CH<sub>2</sub>)<sub>n</sub>X;

n is an integer of 1-3;

X is CONHR<sub>6</sub> or CO<sub>2</sub>R<sub>6</sub>;

R<sub>2</sub> is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;


5 R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF<sub>3</sub>, OCF<sub>3</sub>, SO<sub>2</sub>NHR<sub>6</sub>, NR<sub>6</sub>R<sub>7</sub> or CO<sub>2</sub>R<sub>6</sub>;

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with R<sub>2</sub>;

or a pharmaceutically acceptable salt thereof.

10

3. Compounds of Formula III:



wherein:

15 R<sub>1</sub> is hydroxyl, alkoxy of 1-4 carbons, or -O(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>5</sub>;

n is an integer of 1-3;

R<sub>2</sub> is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

20 R<sub>3</sub>, R<sub>4</sub>, are each, independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF<sub>3</sub>, OCF<sub>3</sub>, SO<sub>2</sub>NHR<sub>5</sub>, NR<sub>5</sub>R<sub>6</sub>, or CO<sub>2</sub>R<sub>5</sub>;


R<sub>5</sub>, R<sub>6</sub> are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where aryl group is substituted with R<sub>2</sub>;

or a pharmaceutically acceptable salt thereof.

25

4. The compound of claim 1, which is 6-Methoxy-5-([4-(trifluoromethoxy)benzyl]amino)methyl)-2-naphthoic acid.

5. The compound of claim 1, which is 5-[[4-(4-Fluorobenzyl)amino]methyl]-6-methoxy-2-naphthoic acid.
6. The compound of claim 1, which is 5-([4-(Aminosulfonyl)benzyl]amino)methyl)-6-methoxy-2-naphthoic acid.
7. The compound of claim 1, which is 5-([4-(Dimethylamino)benzyl]amino)methyl)-6-methoxy-2-naphthoic acid.
8. The compound of claim 1, which is 6-(Carboxymethoxy)-5-([4-(trifluoromethoxy)benzyl]amino)methyl)-2-naphthoic acid.
9. A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises administering to said mammal, a therapeutically effective amount of a compound of Formula I:




wherein:

- R<sub>1</sub> is hydroxyl, alkoxy of 1-4 carbons or -O(CH<sub>2</sub>)<sub>n</sub>X;
- n is an integer of 1-3;
- X is CONHR<sub>6</sub>, or CO<sub>2</sub>R<sub>6</sub>;
- R<sub>2</sub> is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons or acyl of 1-4 carbons;
- R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF<sub>3</sub>, OCF<sub>3</sub>, SO<sub>2</sub>NHR<sub>6</sub>, NR<sub>6</sub>R<sub>7</sub> or CO<sub>2</sub>R<sub>6</sub>;

$R_6$ , and  $R_7$  are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
or a pharmaceutically acceptable salt thereof.

- 5 10. A method of treating or inhibiting type II diabetes in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of compound of Formula I:




wherein:

- $R_1$  is hydroxyl, alkoxy of 1-4 carbons or  $-O(CH_2)_nX$ ;  
 10  $n$  is an integer of 1-3;  
 $X$  is  $CONHR_6$  or  $CO_2R_6$ ;  
 $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;  
 $R_3$ ,  $R_4$  and  $R_5$  are each, independently, hydrogen, halogen, hydroxyl, alkyl of 1-4  
 15 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$  or  $CO_2R_6$ ;  
 $R_6$ , and  $R_7$  are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
 or a pharmaceutically acceptable salt thereof.

20

11. A method of modulating glucose levels in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I:



wherein:

$R_1$  is hydroxyl, alkoxy of 1-4 carbons, or  $-O(CH_2)_nX$ ;

$n$  is an integer of 1-3;


$X$  is  $CONHR_6$  or  $CO_2R_6$ ;

- 5  $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons or acyl of 1-4 carbons;

$R_3$ ,  $R_4$  and  $R_5$  are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$  or  $CO_2R_6$ ;

- 10  $R_6$ , and  $R_7$  are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition which comprises a compound of Formula I:



15

wherein:

$R_1$  is hydroxyl, alkoxy of 1-4 carbons, or  $-O(CH_2)_nX$ ;

$n$  is an integer of 1-3;

$X$  is  $CONHR_6$ , or  $CO_2R_6$ ;

- 20  $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

$R_3$ ,  $R_4$ , and  $R_5$  are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$ , or  $CO_2R_6$ ;

- 25  $R_6$ , and  $R_7$  are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.